Side-by-side comparison of AI visibility scores, market position, and capabilities
Mumbai smartphone-based diagnostic platform with color-change test cards for UTI, diabetes, and kidney tests for 4K+ doctors; YC S21 $2.48M Omidyar Network-backed with Cipla/Sun Pharma/AstraZeneca partnerships for India at-home diagnostics.
Neodocs is a Mumbai, India-based healthtech company — backed by Y Combinator (S21) with $2.48 million raised including a $2 million seed round in February 2024 led by Omidyar Network India with YC, 9Unicorns, Gemba Capital, Titan Capital, and 100Unicorns — providing instant at-home diagnostic test kits with proprietary biochemistry test cards that deliver visual color-change results for conditions including urinary tract infections, diabetes monitoring (HbA1c and glucose), kidney function (creatinine, protein), and general wellness panels without requiring any additional hardware beyond a smartphone camera. Founded in 2020, Neodocs has sold 200,000+ test cards used by 4,000+ doctors across India and has partnerships with major pharmaceutical companies including Cipla, Sun Pharma, and AstraZeneca for co-branded diagnostic test distribution.
Epic holds over 42% of U.S. acute care hospital EHR market share and is embedding AI across 150+ clinical workflows for 2026, while facing antitrust scrutiny.
Epic Systems Corporation was founded in 1979 by Judith Faulkner and is headquartered in Verona, Wisconsin, remaining privately held with Faulkner as majority owner. The company develops large-scale electronic health record systems and reports that more than 305 million patients have a record in Epic, covering the majority of U.S. academic medical centers and large health systems including Kaiser Permanente, Mayo Clinic, Johns Hopkins, and Cleveland Clinic. Epic commands approximately 42% of U.S. acute care hospitals and nearly 55% of acute care hospital beds, making it the undisputed market leader in enterprise EHR.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.